Net Cash Provided by (Used in) Operating Activities of Nurix Therapeutics, Inc. from 30 Nov 2019 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Nurix Therapeutics, Inc. annual and quarterly Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 30 Nov 2019 to 30 Nov 2025.
  • Nurix Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 28 Feb 2025 was $61,087,000, a 46% decline year-over-year.
  • Nurix Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2025 was $249,465,000, a 45% decline from 2024.
  • Nurix Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was $172,584,000, a 112% decline from 2023.
  • Nurix Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $81,365,000, a 49% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $249,465,000 -$76,881,000 -45% 01 Dec 2024 30 Nov 2025 10-K 28 Jan 2026 2025 FY
2024 $172,584,000 -$91,219,000 -112% 01 Dec 2023 30 Nov 2024 10-K 28 Jan 2026 2025 FY
2023 $81,365,000 +$78,442,000 +49% 01 Dec 2022 30 Nov 2023 10-K 28 Jan 2026 2025 FY
2022 $159,807,000 -$75,442,000 -89% 01 Dec 2021 30 Nov 2022 10-K 28 Jan 2025 2024 FY
2021 $84,365,000 -$84,285,000 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023 2022 FY
2020 $80,000* -$681,000 01 Dec 2019 30 Nov 2020 10-K 28 Jan 2022 2021 FY
2019 $601,000 01 Dec 2018 30 Nov 2019 10-K 28 Jan 2022 2021 FY

Nurix Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $61,087,000 -$19,136,000 -46% 01 Dec 2024 28 Feb 2025 10-Q 08 Apr 2025 2025 Q1
Q1 2024 $41,951,000 +$6,501,000 +13% 01 Dec 2023 29 Feb 2024 10-Q 08 Apr 2025 2025 Q1
Q1 2023 $48,452,000 -$5,822,000 -14% 01 Dec 2022 28 Feb 2023 10-Q 10 Apr 2024 2024 Q1
Q1 2022 $42,630,000 -$50,683,000 -629% 01 Dec 2021 28 Feb 2022 10-Q 13 Apr 2023 2023 Q1
Q1 2021 $8,053,000 -$32,919,000 -80% 01 Dec 2020 28 Feb 2021 10-Q 08 Apr 2022 2022 Q1
Q1 2020 $40,972,000 01 Dec 2019 29 Feb 2020 10-Q 13 Apr 2021 2021 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.